<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Wellcome Trust Centre for Human Genetics</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/39F1A6B5-748D-4B32-8738-03E8C9C803FA"><gtr:id>39F1A6B5-748D-4B32-8738-03E8C9C803FA</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Donnelly</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/BB3C4D68-B138-474C-8AEA-C7880419D2C1"><gtr:id>BB3C4D68-B138-474C-8AEA-C7880419D2C1</gtr:id><gtr:firstName>Gil</gtr:firstName><gtr:surname>McVean</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E08F7CF9-201C-4200-ADB0-8467A9989AF4"><gtr:id>E08F7CF9-201C-4200-ADB0-8467A9989AF4</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Holmes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/055C4C4D-A3BB-4FBB-A72C-3B8C78E313E8"><gtr:id>055C4C4D-A3BB-4FBB-A72C-3B8C78E313E8</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>Mark</gtr:otherNames><gtr:surname>Smith</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E68F56EC-6BDB-4B33-AA69-B9F7AB082572"><gtr:id>E68F56EC-6BDB-4B33-AA69-B9F7AB082572</gtr:id><gtr:firstName>Jim</gtr:firstName><gtr:surname>Davies</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A0EF6BCA-9925-46DE-BA83-96D25371ABDF"><gtr:id>A0EF6BCA-9925-46DE-BA83-96D25371ABDF</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Landray</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C3A08924-3211-47F9-A709-DC28DAD85A96"><gtr:id>C3A08924-3211-47F9-A709-DC28DAD85A96</gtr:id><gtr:firstName>Rory</gtr:firstName><gtr:surname>Collins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FL016265%2F1"><gtr:id>594A718D-4BFF-4E43-AA2D-FCF53718A5C4</gtr:id><gtr:title>University of Oxford Big Data Institute: Development &amp;amp; dissemination of efficient analysis methods for large, complex, heterogeneous clinical datasets</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L016265/1</gtr:grantReference><gtr:abstractText>Background: Understanding the determinants of common life-threatening and disabling disease is challenging. Such conditions are typically caused by many different factors (genetic, physiological, behavioural, infectious and environmental), which may be occur at different times of life (including developmental factors as well as those that may occur much later; e.g. cigarette smoking, alcohol, co-morbidity, and treatment). Furthermore the effects may manifest over a range of timescales (immediate to many decades) and time courses (acute, chronic stable, progressive, relapsing/remitting). 

Vision: The University of Oxford Big Data Institute (BDI) sets out to be an international centre of excellence for the analysis of very large and complex biomedical data sets. The Institute will combine world-class academic leadership with a core infrastructure of cutting-edge technology and high calibre scientists. Built upon Oxford's internationally leading expertise in epidemiology, genomics, imaging, computer science, and infectious disease surveillance, the BDI will be a national resource for the development of new analytical methods to facilitate the generation, storage, analysis and sharing of data in very large clinical studies. This work will provide transformative advances in the speed and range of research into the causes and consequences, prevention and treatment of disease, and will be particularly relevant to understanding the role of genetic and environmental influences on common life-threatening and disabling diseases such as cancer, cardiac disease, stroke, and dementia.

Knowledge Transfer: In addition to primary research, the BDI will play a major role in capacity building through training, dissemination of research methods, and stakeholder engagement:
- A new MRC Big Data Training Academy will deliver an extensive, flexible and outward-looking portfolio of training and career development opportunities accessible to researchers of all levels within and outside Oxford, including a new doctoral training programme, support for post-doctoral training fellows, visitor and exchange programmes, and a broad range of short courses suitable for graduate training and continuing professional development.
- Effective collaboration with local, national and international experts (including partnerships with academia, healthcare, and pharmaceutical and IT industries) will enhance the development, evaluation and adoption of new research methods and tools.
- The Institute will work with regulators and other key stakeholders to develop standards for data storage, sharing and analysis; and to promote appropriate and proportionate regulatory and governance approaches that are fit-for-purpose in areas such as privacy, consent, information security, data access and sharing, intellectual property, and the intersection between research and routine practice.
- Public engagement activities will promote understanding, address concerns, and develop trust in &amp;quot;Big Data&amp;quot; approaches to biomedical research.</gtr:abstractText><gtr:technicalSummary>Advances in Big Data offer new ways to conduct health research, with advantages in speed, cost and scope of scientific enquiry. In particular, major advances will come from the development of new methods to integrate and interrogate multiple, complementary datasets simultaneously. The University of Oxford Big Data Institute (BDI) will develop flexible and efficient systems, tools and methods for generating and analysing research-optimized data sets that incorporate relevant clinical information (including bespoke research data and routine clinical information), extensive phenotypic measurements (including imaging, physical and function assessments) and genomic and other laboratory data.

Evaluation of clinical phenotype: The BDI will bring together bioinformaticians, clinical specialists and research users to develop validated algorithms that combine multiple data sources to confirm, clarify and classify clinically and biologically relevant phenotypes in very large studies.

Interpretation of genotype: Current statistical methodologies for assessment of genetic influences on disease (many of which were developed in Oxford) fail in regions of high structural or sequence diversity (e.g. around human HLA and KIR loci, and in many bacterial and eukaryotic pathogens). The BDI will develop novel methods that integrate information from multiple reference sequences, thus extending the ability for researchers to investigate genetic influences on disease pathways.

Combining multi-dimensional phenotypic and genomic data: Building on our experience in clinical informatics and genetic analyses, we will address gaps in the current standards and ontologies. We will develop appropriate statistical methods for the analysis of high-dimensional and highly correlated data in order to allow biologically meaningful associations to be identified robustly. We will also establish an infrastructure that supports appropriate sharing and analysis of biomedical Big Data.</gtr:technicalSummary><gtr:potentialImpactText>The University of Oxford Big Data Institute (BDI) seeks to promote Innovation in Medical Science to produce Transformation in Human Health.

The Institute aims to have broad-ranging influence:

Improved methods and technologies for research: The BDI will bring together existing expertise in large-scale epidemiology, imaging, genomic medicine, bioinformatics, and computer science to create an internationally leading centre of excellence for the analysis of large, complex, heterogeneous data sets for research into the causes and consequences, prevention and treatment of disease. The work of the Institute has the potential to radically extend the boundaries of these individual disciplines (e.g. large-scale epidemiology will require new tools and methodologies to analyse even larger, more complex and rich heterogeneous data), but, the greatest impact is likely to be achieved by close collaboration and working between disparate disciplines (e.g. computer science and epidemiology to develop new analytical tools for routine health data; clinical, imaging and genetic science to better understand the development of dementia). The creation of the Institute will act as a focal point for fostering collaborative engagement with both academic and industrial partners, nationally and internationally.

New advances in science and health: The expertise, methods and systems developed will provide big advances in the ability to understand disease mechanisms and discover new treatment approaches, and will yield significant benefits for clinical care in areas such as infectious disease surveillance &amp;amp; management, and the translation of genomics into routine medical practice. We intend to make our data, methods &amp;amp; tools widely available for scientific researchers.

Capacity building: A new MRC Big Data Training Academy will provide an extensive portfolio of training and development opportunities, suitable for scientists at all stages of their career, and readily accessible to external researchers. These will include a new doctoral training programme in Big Data for Biomedicine, post-doctoral fellowships, a visitor and exchange programme, a large number of short courses suitable for both graduate training and continuing professional development. Much of the training material will be available through a remote learning environment, and the annual Oxford-Stanford Conference on Big Data will provide an opportunity for cross-fertilisation of ideas among the many stakeholders in this research. Thus the multidisciplinary environment of the new Institute will provide substantial opportunities for the development of a new generation of research scientists, equipped to tackle the major medical bioinformatic challenges of Big Data research for the improvement of human health.

Commercial and economic impact: The work seeks to generate new methods, tools and systems for analysing Big Data in biomedicine. These tools will be made widely available through commercial entities spun out of the University, engagement with large IT companies such as Oracle, Microsoft and Google; and strong relationships with pharma who, like academia, are dependent on this type of large sale analysis. We anticipate that the Institute's work will generate substantial investment into UK bioinformatics and health research, and opportunities for spinouts.

Societal impact: The Institute will create a community for engagement, dialogue and debate with government, regulators, policy makers and the public. Developing public trust, understanding and confidence through ongoing active engagement will be a key activity of the new Institute.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-05-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-05-31</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>7000000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Liverpool School of Tropical Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Spatiotemporal patterns of insecticide resistance</gtr:description><gtr:id>72784DB9-4C78-4D0C-8989-DB94A9E7F5EC</gtr:id><gtr:impact>n/a</gtr:impact><gtr:partnerContribution>Joint academic partnership</gtr:partnerContribution><gtr:piContribution>Joint academic partnership</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Festival of Genomics</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9AB5094F-0078-47D9-ABC8-D30085E7CA2D</gtr:id><gtr:impact>N/A</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Alumni Summit</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>73D4A39F-B8EC-4EDC-B6B9-B676D8053037</gtr:id><gtr:impact>AHSN, The Alumni Summit July 2015, Gil McVean and Martin Landray presented</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford Mail interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>CA638159-3C96-4283-B67B-F3108BB9814F</gtr:id><gtr:impact>Interview for 'City is at the forefront of disease prevention', July 2014</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Qualisty by Design for Clinical Trials</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B935E08E-4C87-4498-930D-D4D28ECD83B5</gtr:id><gtr:impact>Clinical Trial Transformation Initiative, Bethseda</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Isis Innovation &amp; Oxford AHSN Technology Showcase 2015</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A82D4CE3-056C-4A3C-8126-5F377A45B5D1</gtr:id><gtr:impact>eHealth &amp;amp; Big Data - Innovation with Impact, Martin Landray</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford Martin Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EEAD0C59-F903-4BA4-8ECB-60CEE007FD4B</gtr:id><gtr:impact>A wealth of new and advancing technologies are changing the way we approach research in healthcare. The use of big data sets, precision medicine and machine learning mean that research studies can be bigger, cheaper and wider reaching than ever before. In this lecture, Professor Martin Landray, Deputy Director of the Big Data Institute, and Professor of Medicine and Epidemiology at the University of Oxford, considered how recent advancements in healthcare technologies have radically changed how we go about medical research, and look at how future innovations could further shape the field.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Online interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E4B83BF1-0A1D-429E-9BBF-3E0A23C564A4</gtr:id><gtr:impact>In this BBC article, professors Martin Landray and Harry Hemingway highlighted the benefits to health from large data sets.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Economist article</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>092F30FB-52E9-4F24-81E9-FF18C2EB60DF</gtr:id><gtr:impact>Interview for the article 'Testing, Testing', July 2014</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AHSN Alumni Summit.  Genomics, Proteomics and Data Session</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D7DD2B24-AF5E-413F-A6D3-3AB56401CC9A</gtr:id><gtr:impact>The session will explore some of the challenges facing academics, clinicians and healthcare providers developing new types of data, connectivity, interpretation and scale. The promise of deeply-enriched genotypic and phenotypic datasets signals expanded horizons for the identification of disease risk, diagnosis and treatment. The data pathway starts with measurements of genotype and phenotype which capture patient data of sufficient breadth and depth. Biobanks are integral to this approach, as are data extraction processes which need to be long-term and based on robust patient engagement. Datasets need to be sufficiently large to ensure that any underlying signal can be pulled out, particularly in a real-time setting. 

Subsequent data integration is both a challenge and opportunity requiring a boundary shift from research to the clinic, ultimately making different datasets function within varied healthcare and commercial settings. Translation of the very best algorithms, and making them work in a high throughput, commercial environment, will require new pathways from research to clinical service provision, which will be dependent on data interpretation and integration at scale. These new pathways will require strong partnerships between diverse organisations that may have different goals and ambitions.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Big Data in Biomedicine</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B7023389-6E42-4202-87C4-8FAD13359A1A</gtr:id><gtr:impact>Bringing together thought leaders in large-scale data analysis and technology to transform the way we diagnose, treat and prevent disease. Learn more: http://stanford.io/1M8v9ra
Martin Landray</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Big Data and Drug Discovery 2013</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2A04522A-3858-45E2-8ECA-F1F342DC2F60</gtr:id><gtr:impact>The Osler Discussion</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at National Academies of Sciences, Engineering and Medicine</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>88EFA6CD-9D1A-4B46-9AD5-1426213F52AC</gtr:id><gtr:impact>10/20/2015 - Session II: Developing Capabilities to Integrate and Use Data from Very Large Data Sets - Martin Landray</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Big Data in Biomedicine 2014</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>418C6C56-D5C7-41B5-BAC3-EF0B7CD0AD95</gtr:id><gtr:impact>Interview for the Big Data in Biomedicien Conference, Stanford</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>67082</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ISSF</gtr:description><gtr:end>2018-11-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>E61564FA-9812-4176-B671-57ABEE3C4958</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Strategic Award: A systematic approach to understanding the biology underpinning GWAS hits</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>C4BC1CBB-F793-4343-B3C0-A0D6FCE5B630</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Accelerating Medicines Partnership: Type 2 Diabetes Knowledge Portal Federated Node Implementation</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Foundation for the National Institutes of Health (FNIH)</gtr:fundingOrg><gtr:fundingRef>FLIC16AMP</gtr:fundingRef><gtr:id>E2CA1B7D-03CB-49B0-BB73-7D1A45548E8A</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000000</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Robertson Foundation</gtr:description><gtr:end>2018-05-02</gtr:end><gtr:fundingOrg>Robertson Foundation</gtr:fundingOrg><gtr:id>53EDF178-A253-4757-AA26-B35C6D3B518B</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1994122</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Strategic Award The Global Health Bioethics Network</gtr:description><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>7BC4CF87-E934-450C-A547-B7B6DFABCE6B</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>71846</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PopART</gtr:description><gtr:end>2018-11-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>B6288216-0549-4DC0-A1D2-F2FB18F9A640</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>530001</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Geospatial Analysis</gtr:description><gtr:end>2020-10-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>BBF341A3-9E13-4A5C-9061-2B37A50EFFF9</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2600000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Geospatial Analyses of Pneumonia, Diarrhea, Malaria, HIV/AIDS, TB and Selected Eradicable Neglected Tropical Diseases</gtr:description><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>C1DE8C58-2A50-4B37-80E2-E3E6B3C2D15B</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1179016</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Geospatial Modelling</gtr:description><gtr:end>2020-10-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>4BA469D5-AB40-4580-A862-3C5E4FD81B2A</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000000</gtr:amountPounds><gtr:country>Hong Kong, Special Administrative Region of China</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Li Ka Shing Foundation</gtr:description><gtr:end>2023-12-02</gtr:end><gtr:fundingOrg>Li Ka Shing Foundation</gtr:fundingOrg><gtr:id>BA8863EB-C98F-47B7-9C7C-2C8CBC17B6F6</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1900000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Genetic Analysis of Populations</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>D932FB05-AD5C-4195-8063-4860FFA2D89E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>23000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Nuffield Department of Population Health</gtr:department><gtr:description>NDPH pump priming</gtr:description><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>969F35DB-A844-46C0-9FBD-AE5F2B44683A</gtr:id><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>23988316</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UK infrastructure for large-scale genomics research</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>79275FA4-459A-4C88-B842-0EBEA6B939B2</gtr:id><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>240761</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PopART Phylo</gtr:description><gtr:end>2018-11-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>4B9B3EBC-1357-4882-944A-1656F57B1413</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR/BRC</gtr:department><gtr:description>BRC3 Sub-theme co-lead with 3 themes: Big Data, Cancer and Antimicrobial Resistance</gtr:description><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>2B7FAD44-40FB-44A2-A0A3-4BF21AC1F25A</gtr:id><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2991157</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Grant to establish Wellcome Centre for Ethics, Innovation, Globalisation and Medicine</gtr:description><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>87F21778-36D7-4029-902D-89236D09AE71</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1064608</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>WIDENLIFE Widening the Scientific Excellence for Maternal Female Reproductive and Fetal Health and Wellbeing</gtr:description><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>0B83B4A2-E24D-4AF4-A9A7-B409B3907DCF</gtr:id><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000805</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>NIH/NICHD P50 Grant Project 2: Common Complex Trait Genetics of Reproductive Phenotypes</gtr:description><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:fundingRef>2P50HD028138-26</gtr:fundingRef><gtr:id>1AA29DDF-38F3-4295-B469-68A6E653ED04</gtr:id><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1551985</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ROADMAP II</gtr:description><gtr:end>2019-05-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>18009002-9C6E-4706-8988-2CB8480DF67C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>110362</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CR-UK Prostate International Cancer Genome Consortium</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>CBE89207-3F6E-41A6-8C49-FA6C10FD3BD3</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>669719</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Malaria Vectors</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>B4D1E5D6-72BD-4FCB-8344-379138C0938E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1052664</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The chnaging endemicity and disease burden of Plasmodium falciparum in Africa since 2000</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>CEAE1064-FB9E-4BD0-9976-C1FB54610E29</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>36000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF NDPH Pump-priming</gtr:description><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>CC24FB53-F215-4579-8F09-2E29EBAB7A23</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>151917</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:department>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:department><gtr:description>NIAID grant Genome based diagnostics for mapping, monitoring and management of insecticide resistance in African malaria vectors</gtr:description><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>D9726AF0-3EA0-48EE-9F2A-B6E8691DC0CA</gtr:id><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2200000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Geospatial modelling for malaria risk stratification and intervention targeting</gtr:description><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>8EA96491-8229-404A-929B-F1ED8F9391AD</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>270497</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Special Training Fellowship in Biomedical Informatics</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N015355/1</gtr:fundingRef><gtr:id>9F2C406E-3194-4E4C-ACC5-C105F80AAC10</gtr:id><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Collaborative Award: Using parasite population genomics to improve understanding of malaria epidemiology</gtr:description><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>48543499-D1AC-4DDC-B674-6E7918BDFB64</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Development &amp;amp; dissemination of efficient analysis methods for large, complex, heterogeneous clinical datasets</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>CC297647-12DE-493E-AF28-3BE8555B30BD</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>External Reference Group for the Ministerial Industry Strategy Group Research through Health Data Porgramme</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A70F6E68-B52E-4EB2-A4FE-FB5E59F8FD61</gtr:id><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO Global Vector Control Response</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>614620B1-50A5-49C0-924D-2905F3534551</gtr:id><gtr:impact>Refined estimates for the global population at risk from key vector-borne diseases (leishmaniasis, American trypanosomiasis, human African trypanosomiasis, dengue, malaria, Japanese encephalitis, lymphatic filariasis, onchoceriasis and yellow fever) for the Global Vecotr Control Response being developed by the WHO</gtr:impact><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>National Health and Biomedical Informatics Institute Academic Workshop, Farr Institute</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AFD92EBB-FC0B-4743-868D-150AF73A8862</gtr:id><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Department of Health, Digital Health Forum</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EF5A0248-38CD-43B0-92AB-9C1ABF0B6CC1</gtr:id><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Office of the Chief Scientist</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>770365E6-0A0B-4B60-B6F5-60765924BB22</gtr:id><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Global Alliance for Genomics and Health, Data Working Group Summit</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>5956B21A-8EDB-4EBF-9726-76412FF614A9</gtr:id><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Provided data to Vector Control gorup of the WHO Global Malaria Programme</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>EA559672-F8FF-4D25-A333-DE93C0CB3ECD</gtr:id><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E4DC250B-F2E4-45B2-97F6-BADDD1CE093E"><gtr:id>E4DC250B-F2E4-45B2-97F6-BADDD1CE093E</gtr:id><gtr:title>Demography and the age of rare variants.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8cb453688692719aabd4a788b0ee93c9"><gtr:id>8cb453688692719aabd4a788b0ee93c9</gtr:id><gtr:otherNames>Mathieson I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6E541738-523C-4B3C-9A16-B6B9A3FA97AC"><gtr:id>6E541738-523C-4B3C-9A16-B6B9A3FA97AC</gtr:id><gtr:title>Exposure Patterns Driving Ebola Transmission in West Africa: A Retrospective Observational Study.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/63906b01248a2d2c2c6b91dad43ada70"><gtr:id>63906b01248a2d2c2c6b91dad43ada70</gtr:id><gtr:otherNames>International Ebola Response Team</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6F3E3858-D161-4C1B-9200-DADD44126B57"><gtr:id>6F3E3858-D161-4C1B-9200-DADD44126B57</gtr:id><gtr:title>Best Practices for Ethical Sharing of Individual-Level Health Research Data From Low- and Middle-Income Settings.</gtr:title><gtr:parentPublicationTitle>Journal of empirical research on human research ethics : JERHRE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/912ef48d42e8331a224cbeb42e1829a5"><gtr:id>912ef48d42e8331a224cbeb42e1829a5</gtr:id><gtr:otherNames>Bull S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1556-2646</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7FD0CADF-E8DF-439B-9E09-24F2AB7BDC20"><gtr:id>7FD0CADF-E8DF-439B-9E09-24F2AB7BDC20</gtr:id><gtr:title>Good and Bad Research Collaborations: Researchers' Views on Science and Ethics in Global Health Research.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b6c6b0bd68dab83386da1c22aa5e1376"><gtr:id>b6c6b0bd68dab83386da1c22aa5e1376</gtr:id><gtr:otherNames>Parker M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1E359D52-ACA9-416E-9BCD-8BE9177754A0"><gtr:id>1E359D52-ACA9-416E-9BCD-8BE9177754A0</gtr:id><gtr:title>Evolution of antibiotic resistance is linked to any genetic mechanism affecting bacterial duration of carriage.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c6f91991ea8f25ac48e390177e6af1ef"><gtr:id>c6f91991ea8f25ac48e390177e6af1ef</gtr:id><gtr:otherNames>Lehtinen S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DDCF02EE-DC31-428E-94BB-D59961CBF0E0"><gtr:id>DDCF02EE-DC31-428E-94BB-D59961CBF0E0</gtr:id><gtr:title>Clinical whole-genome sequencing in severe early-onset epilepsy reveals new genes and improves molecular diagnosis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3160f0533017bb755a07e401f482ae69"><gtr:id>3160f0533017bb755a07e401f482ae69</gtr:id><gtr:otherNames>Martin HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/44822F5E-EA1D-49EA-9FFC-635DD03908FD"><gtr:id>44822F5E-EA1D-49EA-9FFC-635DD03908FD</gtr:id><gtr:title>Mutational signatures of ionizing radiation in second malignancies.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8ca6a1dc725620cbec6faf4baf7d323b"><gtr:id>8ca6a1dc725620cbec6faf4baf7d323b</gtr:id><gtr:otherNames>Behjati S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FBF77BF0-CD5C-4C96-948B-A34E74DBCDBE"><gtr:id>FBF77BF0-CD5C-4C96-948B-A34E74DBCDBE</gtr:id><gtr:title>Phylogenetic Tools for Generalized HIV-1 Epidemics: Findings from the PANGEA-HIV Methods Comparison.</gtr:title><gtr:parentPublicationTitle>Molecular biology and evolution</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6cd76249779913dfda6133932a845c6d"><gtr:id>6cd76249779913dfda6133932a845c6d</gtr:id><gtr:otherNames>Ratmann O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0737-4038</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AF642416-133A-4C5F-A9FE-1849E8C935C8"><gtr:id>AF642416-133A-4C5F-A9FE-1849E8C935C8</gtr:id><gtr:title>The ethics of sustainable genomic research in Africa.</gtr:title><gtr:parentPublicationTitle>Genome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b6c6b0bd68dab83386da1c22aa5e1376"><gtr:id>b6c6b0bd68dab83386da1c22aa5e1376</gtr:id><gtr:otherNames>Parker M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-7596</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/55690F2F-3876-445F-A811-CDF5DB53C174"><gtr:id>55690F2F-3876-445F-A811-CDF5DB53C174</gtr:id><gtr:title>A transmission-virulence evolutionary trade-off explains attenuation of HIV-1 in Uganda.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0351bae3aa5dfd63500c2a34e3a65992"><gtr:id>0351bae3aa5dfd63500c2a34e3a65992</gtr:id><gtr:otherNames>Blanquart F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/949FF2A2-08A0-46FD-AAFE-DE49F7868EE7"><gtr:id>949FF2A2-08A0-46FD-AAFE-DE49F7868EE7</gtr:id><gtr:title>Large Variations in HIV-1 Viral Load Explained by Shifting-Mosaic Metapopulation Dynamics.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1a685608f8103a7db1465d4d9cd9dbdf"><gtr:id>1a685608f8103a7db1465d4d9cd9dbdf</gtr:id><gtr:otherNames>Lythgoe KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8CC95CA3-6F9E-433F-B7C1-7E25B6BE1E08"><gtr:id>8CC95CA3-6F9E-433F-B7C1-7E25B6BE1E08</gtr:id><gtr:title>UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/56022eb4712f9703d94edab35e2b236b"><gtr:id>56022eb4712f9703d94edab35e2b236b</gtr:id><gtr:otherNames>Sudlow C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L016265/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1A41A859-2076-46E6-B80F-CE4E1E8EDC1D</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.5  Resources and infrastructure (underpinning)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>